Healio April 10, 2018
Lee TT, Kesselheim AS

In a new commentary published in Annals of Internal Medicine, experts suggest that the FDA’s Digital Health Software Precertification Program may lead to less rigorous FDA oversight and studies of safety and effectiveness of marketed digital health apps, with uncertain patient outcomes.

“The [FDA’s] Digital Health Software Precertification (Pre-Cert) Program is designed to expedite regulatory review for companies that demonstrate quality and organizational excellence in software development,” Theodore T. Lee, BA, from Yale University, and Aaron S. Kesselheim, MD, JD, MPH, from Brigham and Women’s Hospital and Harvard Medical School, wrote. “Although Pre-Cert is intended to promote the worthy goals of access and innovation in digital health, many questions have been raised.”

SEE ALSO
...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Apps, Digital Health, FDA, Govt Agencies, mHealth, Technology
FDA approves 1st monotherapy drug for treatment-resistant depression
FDA's AI Lifecycle & Scientific Information Guidance Documents
Opinion: Three former FDA officials: Here’s what Trump and his nominees need to know
Inflammatix Scores FDA Approval for Precision Infection Test
FDA Approves Spravato as Monotherapy for Major Depressive Disorder

Share This Article